Opioid-use-disorder - Articles - Page 3

EXPERT Q&A

Benzodiazepines: Old Medicines, New Concerns

June 10, 2020

Kenneth Morford, MD
Assistant Professor and Program Director, Collaborative Behavioral Health & Addiction Medicine in Primary Care (CHAMP) at Yale School of Medicine. Dr. Morford has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Benzodiazepine use is on the rise, and is implicated with a significant portion of opioid-related overdose deaths. Dr. Morford gives the latest on benzodiazepine prevalence and suggests strategies to employ in addiction treatment settings when working with patients who use benzodiazepines.

Reducing the Stigma of Addiction Through Language and Terminology

March 30, 2020

Specific terms and phrases, when used among health professionals, can lead to more punitive treatment plans and increased stigma perceived by patients. Learn the evidence base behind recent recommendations among medical societies, journals, and periodicals to use more person-centered language.

EXPERT Q&A

Personal Privacy Versus Public Safety: Addiction Among Health Professionals

March 30, 2020

Paul H. Earley, MD, DFASAM

Paul H. Earley, MD, DFASAM
Medical director of the Georgia Professionals Health Program, Inc. Distinguished Fellow of ASAM. President of the Federation of State Physician Health Programs. Dr. Earley has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Paul Earley, president-elect of the Federation of Physician Health Programs, outlines the offerings of physician health programs, how to engage yourself or colleagues in treatment, and how treatment may interface with medical boards.

CLINICAL UPDATE

Learning From the Successes of Physician Health Programs

March 30, 2020

Physician health programs have boasted high rates of treatment retention and abstinence rates, yet have also been the targets of criticism. Here we review what the practicing clinician can learn from these programs and describe current controversies.

Perioperative Management of Patients on Buprenorphine Maintenance

November 22, 2019

Gregory Acampora, MD

Gregory Acampora, MD

Psychiatrist, Pain Management Center, Massachusetts General Hospital/Harvard Center for Addiction Medicine, Boston, MA. Assistant Professor, Harvard Medical School.

Dr. Acampora has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

For patients on buprenorphine maintenance facing surgery, it is crucial to balance the need to minimize pain while addressing the risk of relapse. In this interview, Dr. Gregory Acampora guides us through the specifics on perioperatively managing patients on varying doses of buprenorphine maintenance.

Treating Addiction in Patients Transitioning to/from Incarceration

August 1, 2019

Karen Cropsey, PsyD

Karen Cropsey, PsyD

Conatser Turner Endowed Professor of Psychiatry, University of Alabama at Birmingham.

Dr. Cropsey has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Addiction treatment during incarceration is limited, and release from incarceration presents its own set of challenges. In this QA interview, Dr. Karen Cropsey discusses effective treatment options for patients with substance use disorders transitioning to or from incarceration.

New Generic Versions of Naloxone

August 1, 2019

Talia Puzantian, PharmD, BCPP.

Talia Puzantian, PharmD, BCPP. Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Naloxone, a rescue medication effective for reversing opioid overdose, will soon be available in two generic forms for layperson use. This news of note summarizes these generic, lower-cost products.

Opioid Use Disorder: Is There an App for That?

August 1, 2019

Joshua Sonkiss, MD.

Joshua Sonkiss, MD. Dr. Sonkiss has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This News of Note discusses the first FDA-approved mobile app for SUDs, called reSET-O. Classified as a mobile medical app (MMAs), reSET-O can be used as an adjunct to outpatient opioid use disorder treatment. Unlike most apps, reSET-O requires a prescription to unlock and use.

Can Buprenorphine Improve PTSD Symptoms?

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 retrospective study examines the potential benefits of using buprenorphine/naloxone to treat co-occurring PTSD and opioid use disorder.

Oral vs Extended-Release Naltrexone for Opioid Use Disorder

May 21, 2019

Jessica Goren, PharmD.

Jessica Goren, PharmD. Dr. Goren has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone?